Annals of Clinical Biochemistry > Annals of Clinical Biochemistry Online First > 10.1258/acb.2008.008133

This Article Full Text (PDF) All Versions of this Article: acb.2008.008133v1 46/1/5    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mackness, B. Articles by Mackness, M. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Personal View

High-density lipoprotein: why all the fuss?

Bharti Mackness and Mike Mackness

Pontech House, Cote Green Road, Marple Bridge, Stockport SK6 5EW, UK

Corresponding author: Dr Mike Mackness. Email: mike.Mackness{at}manchester.ac.uk

The current search for new treatments to combat coronary heart disease (CHD) is centred on increasing HDL-cholesterol. The failure of the CETP inhibitor torcetrapib may force a rethink. This perspective briefly reviews the antiatherosclerotic properties of HDL and ways HDL-cholesterol concentration can be raised, but argues – in light of the fact that HDL-cholesterol concentration does not reflect the protective properties of HDL particles – that this approach is flawed and a different approach, targeting know antiatherosclerotic components of HDL, is required.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. De Keyzer, S.-A. Karabina, W. Wei, B. Geeraert, D. Stengel, J. Marsillach, J. Camps, P. Holvoet, and E. Ninio Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2041 - 2046. [Abstract] [Full Text] [PDF]